ConCallIQ
Go Pro
Home › Corona Remedies › PAT History

Corona Remedies PAT History — Quarter by Quarter

Corona Remedies's pat moved from ₹52 Cr in Q2 FY26 to ₹45 Cr in Q4 FY26, a -13.5% change over 3 quarters. The table keeps each quarter linked back to the underlying earnings page.

PAT by Quarter

QuarterPAT (₹ Cr)YoY Change
Q4 FY26₹45 Cr+33.4%
Q2 FY26₹52 Cr+22%
Q3 FY26₹41 Cr+24%

What management said about pat

G

Q4 FY26 · 20%+ PAT growth in FY27

Management guided for 20%+ PAT growth in FY27.

G

Q2 FY26 · 15% revenue CAGR and 20% PAT/EPS growth for next 3-4 years

Management targets 15% revenue CAGR and 20% PAT or EPS growth over the next 3-4 years, underpinned by organic growth, brand acquisitions, and new therapy entries.

G

Q3 FY26 · PAT growth of 20% for FY26

Profit after tax growth target of 20% for the full year, with 9M PAT growth at 31%.

G

Q3 FY26 · Launch of GLP-1 injectable in March 2026

Plan to launch GLP-1 injectable (brand Wing Tide) on patent expiry day in March 2026.